References
- Bodey G P, Rodriguez V, Cabanillas F, Freireich E J. Protected environment-prophylactic antibiotic program for malignant lymphoma. Randomized trial during chemotherapy to induce remission. Am J Med 1979; 66: 74–81
- Gianni A M, Bregni M, Siena S, Brambilla C, Nicola M D, Lombardi F, et al. High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B cell lymphoma. N Eng J Med 1997; 336: 1290–1297
- Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295
- Verdonck L, Dekker A W, de Gast G C. Salvage therapy with ProMACE-MOPP followed by intensive chemoradiotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphoma who failed to respond to first-line CHOP. J Clin Oncol 1992; 12: 1949–1954
- Verdonck L, van Putten W LJ, Hagenbeek A, Schouten H C, Sonneveld O, van Imhoff G W, et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Eng J Med 1995; 332: 1045–1051
- Peterson B, Johnson J, Shipp M, Barcos M, Gockerman J, Canellos G, et al. High Dose CHOP. A phase II study of initial treatment in aggressive non-Hodgkin lymphoma: Cancer and Leukemia Group B 9351. Leuk Lymphoma 2007; 48: 870–880
- Pfreundschuh M, Trumper L, Kloess M, Schmits R, Feller A C, Rube C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641